Fund sues Cephalon over Valeant bid

Valeant Pharmaceuticals ($VRX) may get some help in buying Cephalon ($CEPH) from one of that company's investors. A Pennsylvania pension fund has sued Cephalon, saying management has simply refused to consider Valeant's $5.7 billion buyout offer. And that, the pension fund alleges, shows the company is ignoring the best interests of the shareholders. Report

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.